The Impact of Time Horizons on QALY Calculations in Healthcare
By Melike Belenli Gümüş
June 10, 2024
Introduction
Quality-adjusted life years (QALYs) play a pivotal role in determining the cost-effectiveness of treatments, particularly within the National Health Service (NHS) of England and Wales. While theoretically equal, the practical application of QALYs has raised concerns, especially regarding rare diseases and unique patient populations. This article explores the impact of time horizons on QALY calculations and implicitly funding decisions for healthcare treatments.
Understanding QALYs and NICE’s Evaluation
QALYs blend clinical benefit and treatment duration, with the National Institute for Health and Care Excellence (NICE) using them to assess cost-effectiveness. Treatments exceeding GBP 30,000 per QALY gained face funding challenges. However, the application of QALYs across diverse patient groups has sparked debates on fairness and transparency in decision-making processes.
Figure 1: The concept of Quality-adjusted life years (QALYs) combines the clinical benefit of a treatment with the time duration over which the patient benefits. Longer time horizons result in the accumulation of more QALYs. For instance, in a scenario where Treatment A has a quality of life of 0.8 over 40 years and Treatment B has a quality of life of 0.4 over 80 years, both treatments yield the same QALY gain.
Case Studies: Afamelanotide and Givosiran
Examining evaluations of afamelanotide for erythropoietic protoporphyria and givosiran for acute hepatic porphyria reveals discrepancies in time horizons. The length of time considered for treatment impacts QALY gains and subsequent funding recommendations, highlighting the need for consistency and realism in assessments.
Figure 2: Treatment duration in the clinical reality vs. time horizon used to calculate the QALY gain of afamelanotide for treating erythropoietic protoporphyria (above) and givosiran for treating acute hepatic porphyria (below) at NICE.
Analysis of Time Horizons in HST Programme
A comprehensive review of time horizons in Highly Specialised Technologies (HST) evaluations uncovers a trend towards extended durations, sometimes surpassing expected treatment periods or life expectancies. Extended time horizons can alter perceived treatment benefits and impact funding decisions, potentially influencing resource allocation within the healthcare system.
Implications and Recommendations
The study underscores the importance of aligning time horizons with clinical realities to ensure equitable funding decisions. Transparent reporting and methodological consistency in QALY calculations are crucial for promoting fairness and trust in healthcare funding processes. Addressing discrepancies and rationalising parameters like time horizons can enhance the integrity of decision-making frameworks.
Conclusion
The analysis calls for a re-evaluation of time horizons in QALY calculations to uphold fairness and accuracy in healthcare funding assessments. By fostering transparency, consistency, and evidence-based decision-making, organisations like NICE can better serve diverse patient populations and uphold the principles of equitable healthcare access.
🚀 Is Europe poised to reclaim its leadership in life sciences by 2030?
The European Commission has unveiled a game-changing strategy aimed at transforming the EU into the world’s leading hub for life sciences, tackling critical challenges in health, biotechnology, and sustainability. With strategic investments and reforms, this initiative promises to bridge the innovation gap and enhance public health outcomes across the continent.
Curious about how these plans will impact the life sciences landscape? Explore the full insights of this exciting strategy!
🔍 Are we truly getting the full story on high-cost medications like ticagrelor?
A recent BMJ investigation has raised alarm bells over the integrity of data from pivotal studies on AstraZeneca’s ticagrelor, revealing significant misreporting and missing data that may undermine its clinical benefits. This exposes critical implications for health economics, regulatory oversight, and market access.
Curious about how these findings could reshape perceptions of drug efficacy and safety? Dive into the full article to uncover the truth behind the numbers.
🌍 Are we overlooking the power of self-care in Europe’s public health strategy?
The rise of self-care public health is reshaping how minor ailments are managed across the continent, leading to remarkable economic and productivity benefits. With annual savings of €36 billion and lifestyle improvements for consumers, self-care is proving to be a game-changer for healthcare systems.
Explore how embracing self-care can alleviate pressure on healthcare providers and enhance individual well-being. Dive into the full article to discover the implications for health economics and public policy!
#SyenzaNews #HealthEconomics #HealthcarePolicy
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.
